BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
Tweet Send to a Friend
Cantor Fitzgerald analyst Steven Seedhouse raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $26.00 (from $24.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
